Monday , December 18 2017
Home / Resources / Articles / EASD: Targeting the Adaptive Glycosuria Response of SGLT2 Inhibitors Could Help Weight Loss

EASD: Targeting the Adaptive Glycosuria Response of SGLT2 Inhibitors Could Help Weight Loss

Combining SGLT2 inhibitor treatment with strategies to maintain energy intake or curb appetite could be an avenue for weight loss….

How helpful was this article? (Please vote.)
{mainvote} 

Ferrannini and colleagues collected data by analyzing 86 patients (age, 58 ± 9 years; BMI, 29.8 ± 4.5 kg/m²; HbA1c, 7.8 ± 0.8%; fasting plasma glucose,169 ± 41 mg/dL; estimated glomerular filtration rate, 89 ± 19 mL/min/1.73m²). The patients received empagliflozin 25 mg/day for 90 weeks. Researchers looked at body weight, FPG, eGFR, and serum creatinine as outcomes.

Both single-dose and chronic treatment caused glycosuria during fasting (median of 7.8). "At 90 weeks, weight loss averaged –3.2 ± 4.2 kg (range, –17 to 5.5 kg). During 90 weeks, the average urinary glucose excretion was 54 ± 15 g/day (fractional UGE, 45 ± 4%)." During the study, patients lost around 38% to 53% of the weight predicted by their glycosuria.

Practice Pearl:

  • Combining SGLT2 inhibitors treatment with strategies to maintain energy intake or curb appetite could be an avenue for weight loss

Ferrannini, Giulia. "Adaptive Glycosuria Response with SGLT2 Therapy Holds Potential for Weight Loss." EASD 2014, 25 Sept. 2014